STOCKHOLM, Sweden – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that all patients included in the company's Phase III study with AKP02 against mild to moderate psoriasis have now been fully treated. This means that the collected data can be analysed, with results from the study expected towards the end of […]
Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) can today announce that the last patient has been enrolled in the ongoing Phase III study of AKP02 against mild to moderate psoriasis. The recruitment is thus complete. Results from the study are expected in the third quarter of 2022. “We are very pleased to have […]
The following resolutions were passed at the annual general meeting (the “AGM”) of Lipidor AB (publ) (“the Company”) on 2 June. The annual general meeting was carried out through advance voting (postal voting) only. Adoption of income statement and balance sheet and discharge from liability The AGM resolved to adopt the income statement for the […]
STOCKHOLM, Sweden, 20 May 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half of the patients have now been enrolled in the Phase III study of AKP02 skin spray for mild to moderate psoriasis, with the last patient expected to begin treatment in June 2022. Topline results from the Phase […]
STOCKHOLM, Sweden, 5 May 2022 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period 1 January – 31 March 2022. The report is available on the company's website lipidor.se (https://lipidor.se/lipidor-ab-delarsrapport-q1-2022/) and in the attached pdf. Summary of year-end report During the first quarter, the first patients were […]
STOCKHOLM, Sweden, 3[rd] May 2022: The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (“Lipidor” or the “Company”) are hereby given notice of the Annual General Meeting (the “AGM”) to be held on 2 June 2022. N.B. This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall […]
STOCKHOLM, Sweden, 28th April 2022 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its annual report for the financial year 2021. The report is available on the company's website lipidor.se (https://lipidor.se/lipidorar2021_2022-04-28/) and in the attached pdf. The information was provided for publication by Lipidor’s CEO on 28th April 2022 at 3.30 pm […]
STOCKHOLM, Sweden, 25 March 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) is announcing that the company has strengthened its operational team with the recruitment of Marianne Avila to the position of Supply Chain & Operations Manager. At Lipidor, Marianne Avila will strengthen the operational team and contribute to development, primarily in […]
STOCKHOLM, Sweden, 23 February 2022 – Today, Lipidor AB publishes its year-end report for the period 1 January – 31 December 2021. The report is available on the company's website lipidor.se (https://lipidor.se/lipidor-ab-delarsrapport-q4-2021/) and in the attached pdf. Summary of year-end report During the year, Lipidor's most important milestone to date was reached when a commercially exclusive […]
STOCKHOLM, Sweden, 26[th] January 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today reports that the first patients have been enrolled in a Phase III clinical study using AKP02 cutaneous spray (calcipotriol + betamethasone dipropionate 0.005 %/0.05 %) against mild to moderate psoriasis. Results from the study are expected to be presented […]